株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

前立腺癌:フランスにおける治療薬の予測と治療分析(〜2020年)

Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020

発行 GlobalData 商品コード 141954
出版日 ページ情報 英文 216 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
前立腺癌:フランスにおける治療薬の予測と治療分析(〜2020年) Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020
出版日: 2010年12月01日 ページ情報: 英文 216 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、フランスにおける前立腺癌治療薬市場の動向と競合、パイプライン分析、参入企業のプロファイル、アンメットニーズ、開発中の薬剤動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 疾病の概要

  • 概要
  • 疫学
  • 病因
  • 症状
  • 診断
  • 病理学
  • 治療
  • 治療ガイドライン

第3章 市場の特性

  • フランス
    • 市場規模
    • 促進因子と障壁
    • 市場影響
    • 予測
    • 薬剤売上
    • 薬価と償還

第4章 競合評価

  • 戦略的競合評価
  • 上市分析と売上予測
  • 製品プロファイル

第5章 パイプライン評価

  • 概要
  • 開発段階別パイプライン分析
  • 作用機序別パイプライン
  • 戦略的パイプライン評価
  • 前立腺癌パイプライン動向
  • 研究開発パートナー
  • 最も有望な薬剤プロファイル
  • 前治験段階
  • 第1相
  • 第2相
  • 第3相

第6章 アンメットニーズと標的製品プロファイル

第7章 戦略的評価

第8章 企業プロファイル

第9章 M&A動向

第10章 専門家の見解

第11章 付録

図表

目次
Product Code: GDHC011DFR

Summary

GlobalData' s pharmaceutical report, “Prostate Cancer - France Drug Forecasts and Treatment Analysis to 2020” is an essential source of information and analysis on the French prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the French prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the French prostate cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized French prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
- Analysis of unmet need in the market and target product profiles including opportunity for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
- An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
- Analysis of the current and future market competition in the French Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
- Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in France.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the French prostate cancer therapeutics market.
- Understanding the treatment preferences of physicians for each disease state and across treatment flow.
- Accessing market sizing forecasts and quantified growth opportunities in the French prostate cancer therapeutics market up to 2020.
- Quantifying the patient population in the French to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
- Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
- Track drug sales in the French prostate cancer therapeutics market from 2001 to 2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the French prostate cancer therapeutics market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Disease Overview

  • 2.1. Overview
    • 2.1.1. TNM (Tumor, Nodes, Metastasis) Staging System
    • 2.1.2. Jewett-Whitmore system
  • 2.2. Epidemiology
  • 2.3. Etiology
  • 2.4. Symptoms
    • 2.4.1. Localized or Locally Advanced Prostate Cancer
    • 2.4.2. Metastatic Prostate Cancer
  • 2.5. Diagnosis
    • 2.5.1. Digital Rectal Examination
    • 2.5.2. Prostate Specific Antigen Test
    • 2.5.3. Transrectal Ultrasound
    • 2.5.4. Prostate Biopsy
  • 2.6. Pathology
    • 2.6.1. Grading
  • 2.7. Treatment
    • 2.7.1. Watchful Waiting
    • 2.7.2. Radiation therapy
    • 2.7.3. Surgery
    • 2.7.4. Hormone therapy
    • 2.7.5. Chemotherapy Options
    • 2.7.6. Other Treatments Being Studied
  • 2.8. Treatment Guidelines

3. Market Characterization

  • 3.1. France
    • 3.1.1. Market Size
    • 3.1.2. Drivers & Barriers
    • 3.1.3. Impact on the Market
    • 3.1.4. Forecasts
    • 3.1.5. Drug Sales
    • 3.1.6. Pricing & Reimbursements

4. Competitor Assessment

  • 4.1. Strategic Competitor Assessment
    • 4.1.1. Overview
    • 4.1.2. Benchmarking
    • 4.1.3. Current Competitor Assessment
  • 4.2. Launch Analysis and Sales Forecasts
  • 4.3. Product Profiles
    • 4.3.1. Taxotere (docetaxel)
    • 4.3.2. Casodex (Bicalutamide)
    • 4.3.3. Zoladex (Goserelin)
    • 4.3.4. Eligard (leuprolide acetate)
    • 4.3.5. Firmagon (degarelix)
    • 4.3.6. Novantrone (Mitoxantrone hydrochloride)
    • 4.3.7. Emcyt (estramustine)
    • 4.3.8. Trelstar (triptorelin)
    • 4.3.9. Eulexin
    • 4.3.10. Delestrogen
    • 4.3.11. Gynodiol
    • 4.3.12. Estrace tablet
    • 4.3.13. Tace
    • 4.3.14. Nilandrone
    • 4.3.15. Premarin
    • 4.3.16. Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol

5. Pipeline Assessment

  • 5.1. Overview
  • 5.2. Pipeline Analysis by Phase of Development
  • 5.3. Pipeline by Mechanism of Action
  • 5.4. Strategic Pipeline Assessment
    • 5.4.1. Technology Trends Analytical Framework
  • 5.5. Trends in Prostate Cancer Pipeline
    • 5.5.1. More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
    • 5.5.2. Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
    • 5.5.3. Failure of Key Molecules to Achieve Positive Results in Phase III Development
  • 5.6. Partners in Research and Development
    • 5.6.1. Licensing Agreements by Phase of Development
    • 5.6.2. Licensing Agreements by Geography
    • 5.6.3. Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
  • 5.7. Most Promising Drugs' Profiles
    • 5.7.1. Provenge (sipuleucel-T)
    • 5.7.2. Jevtana (cabazitaxel)
    • 5.7.3. Aflibercept (VEGF Trap)
    • 5.7.4. Ipilimumab
    • 5.7.5. Abiraterone Acetate (CB7630)
    • 5.7.6. Zibotentan (ZD4054)
    • 5.7.7. Sprycel (dasatinib)
    • 5.7.8. MDV3100
  • 5.8. Prostate Cancer Pipeline - Pre-clinical Phase
  • 5.9. Prostate Cancer Pipeline - Phase I
  • 5.10. Prostate Cancer Pipeline - Phase II
  • 5.11. Prostate Cancer Pipeline - Phase III
  • 5.12. Key Takeaway

6. Unmet Need and Target Product Profile

  • 6.1. Unmet Need
    • 6.1.1. Hormone-independent Metastatic Prostate Cancer Therapy
    • 6.1.2. Hormone-dependent Metastatic Prostate Cancer Therapy
  • 6.2. Opportunity for Target Product
  • 6.3. Target Product Profile
    • 6.3.1. Ideal Characteristics
    • 6.3.2. Target Product Description
  • 6.4. Key Takeaway

7. Strategic Assessment

  • 7.1. Key Events Impacting the Future Market
  • 7.2. Market Impact Analysis
  • 7.3. Future Market Scenario
  • 7.4. Company Analysis
    • 7.4.1. Market Leadership
    • 7.4.2. Future Players in the Market
  • 7.5. Key Takeaway

8. Company Profiles

  • 8.1. Sanofi-aventis
    • 8.1.1. Business Description
    • 8.1.2. Financial Overview
    • 8.1.3. SWOT Analysis
    • 8.1.4. Oncology Focus
  • 8.2. Pfizer Inc.
    • 8.2.1. Business Description
    • 8.2.2. Financial Overview
    • 8.2.3. SWOT Analysis
    • 8.2.4. Oncology Focus
  • 8.3. AstraZeneca
    • 8.3.1. Business Description
    • 8.3.2. Financial Overview
    • 8.3.3. SWOT Analysis
    • 8.3.4. Oncology Focus
  • 8.4. Bristol-Myers Squibb
    • 8.4.1. Business Description
    • 8.4.2. Financial Overview
    • 8.4.3. SWOT Analysis
    • 8.4.4. Oncology Focus
  • 8.5. Medivation
    • 8.5.1. Business Description
    • 8.5.2. SWOT Analysis
    • 8.5.3. Oncology Focus
  • 8.6. Takeda Pharmaceuticals
    • 8.6.1. Business Description
    • 8.6.2. SWOT Analysis
  • 8.7. Dendreon Corporation
    • 8.7.1. Business Description
    • 8.7.2. SWOT Analysis
  • 8.8. Johnson and Johnson
    • 8.8.1. Business Description
    • 8.8.2. SWOT Analysis
    • 8.8.3. Oncology Focus
  • 8.9. Auron Healthcare GmbH
    • 8.9.1. Business Description
  • 8.10. Oncogenex Pharmaceuticals, Inc.
    • 8.10.1. Business Description
  • 8.11. Agennix AG
    • 8.11.1. Business Description
  • 8.12. GTx, Inc.
    • 8.12.1. Business Description
  • 8.13. GlaxoSmithKline plc.
    • 8.13.1. Business Description
    • 8.13.2. Financial Overview
    • 8.13.3. SWOT Analysis
    • 8.13.4. Oncology Focus

9. M&A Analysis

  • 9.1. Key Highlights
  • 9.2. Key Deals' Analysis
    • 9.2.1. Johnson & Johnson Acquires Cougar Biotechnology
    • 9.2.2. Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
    • 9.2.3. Tolmar Holding Acquires QLT USA from QLT
    • 9.2.4. Biomarin Pharmaceutical to Acquire Lead therapeutics
    • 9.2.5. Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co.
    • 9.2.6. Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs
    • 9.2.7. VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax
    • 9.2.8. GPC Biotech Merges with Agennix
    • 9.2.9. Eli Lilly Acquires ImClone
    • 9.2.10. BBM Holdings Acquires YM BioSciences
    • 9.2.11. Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals
  • 9.3. M&A Deals by Geography
  • 9.4. M&A Deals by Deal Size

10. Expert Opinion

  • 10.1. France

11. Appendix

  • 11.1. Market Definitions
  • 11.2. Abbreviations
  • 11.3. Research Methodology
    • 11.3.1. Coverage
    • 11.3.2. Secondary Research
    • 11.3.3. Forecasting
    • 11.3.4. Primary Research
    • 11.3.5. Expert Panel validation
  • 11.4. Contact Us
  • 11.5. Disclaimer
  • 11.6. Sources

List of Tables

  • Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010
  • Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010
  • Table 3: Prostate Cancer, France, Sales Value ($m), 2001-2009
  • Table 4: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009
  • Table 5: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2001-2009
  • Table 6: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2001-2009
  • Table 7: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020
  • Table 8: Prostate Cancer, France, Annual Cost of Therapy ($), 2009-2020
  • Table 9: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2009-2020
  • Table 10: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2009-2020
  • Table 11: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010
  • Table 12: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2009-2020
  • Table 13: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010
  • Table 14: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2009-2020
  • Table 15: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010
  • Table 16: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2009-2020
  • Table 17: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010
  • Table 18: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010
  • Table 19: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010
  • Table 20: Prostate Cancer, France, Benchmarking Major Marketed Products, 2010
  • Table 21: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010
  • Table 22: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010
  • Table 23: Prostate Cancer, Global, Eligard, Incidence of Adverse Effects, 2010
  • Table 24: Prostate Cancer, Global, Eligard, Regulatory Approval by Region
  • Table 25: Prostate Cancer, Global, Licensing Agreements, 2009-2010
  • Table 26: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010
  • Table 27: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010
  • Table 28: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010
  • Table 29: Prostate Cancer, Global, Phase I Pipeline, August 2010
  • Table 30: Prostate Cancer, Global, Phase II Pipeline, August 2010
  • Table 31: Prostate Cancer, Global, Phase III Pipeline, August 2010
  • Table 32: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
  • Table 33: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010
  • Table 34: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010
  • Table 35: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010
  • Table 36: Prostate Cancer, Global, M&A Deals by Geography, 2010

List of Figures

  • Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
  • Figure 2: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2001-2009
  • Figure 3: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009
  • Figure 4: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2001-2009
  • Figure 5: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2001-2009
  • Figure 6: Prostate Cancer, France, Market Drivers and Restraints, 2009
  • Figure 7: Prostate Cancer, France, Historical Events Impact on the Market, 2010
  • Figure 8: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020
  • Figure 9: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009-2020
  • Figure 10: Prostate Cancer Therapeutics Market, France, Patient Volume ('000s), 2009-2020
  • Figure 11: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns ('000s), 2009-2020
  • Figure 12: Prostate Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009-2020
  • Figure 13: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
  • Figure 14: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
  • Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010
  • Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010
  • Figure 17: Prostate Cancer Therapeutics Market, France, Sales Forecast by Therapies, 2001-2020
  • Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure
  • Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010
  • Figure 20: Prostate Cancer, France, Taxotere, Sales ($m), 2004-2020
  • Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure
  • Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 1995-2010
  • Figure 23: Prostate Cancer, France, Casodex, Sales ($m), 1995-2020
  • Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure
  • Figure 25: Prostate Cancer, France, Zoladex, Sales Forecast ($m), 1998-2020
  • Figure 26: Prostate Cancer, Global, Eligard , Chemical Structure
  • Figure 27: Prostate Cancer, France, Leuprolide (Eligard), Sales Forecast ($m), 2001-6020
  • Figure 28: Prostate Cancer, Global, Firmagon, Chemical Structure
  • Figure 29: Prostate Cancer, France, Firmagon, Sales Forecast ($m), 2009-2020
  • Figure 30: Prostate Cancer, Global, Novatrone, Chemical Structure
  • Figure 31: Prostate Cancer, France, Mitoxantrone, Sales Forecast ($m), 2001-2020
  • Figure 32: Prostate Cancer, Global, Emcyt, Chemical Structure
  • Figure 33: Prostate Cancer, France, Estramustine, Sales Forecast ($m), 2001-2020
  • Figure 34: Prostate Cancer, Global, Trelstar, Chemical Structure
  • Figure 35: Prostate Cancer, Global, Eulexin, Chemical Structure
  • Figure 36: Prostate Cancer, Global, Delestrogen, Chemical Structure
  • Figure 37: Prostate Cancer, Global, Gynodiol, Chemical Structure
  • Figure 38: Prostate Cancer, Global, Estrace, Chemical Structure
  • Figure 39: Prostate Cancer, Global, Tace, Chemical Structure
  • Figure 40: Prostate Cancer, Global, Nilandrone, Chemical Structure
  • Figure 41: Prostate Cancer, Global, Premarin, Chemical Structure
  • Figure 42: Prostate Cancer, France, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020
  • Figure 43: Prostate Cancer, Global, Clinical Trials by Therapy, 2010
  • Figure 44: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010
  • Figure 45: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010
  • Figure 46: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
  • Figure 47: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010
  • Figure 48: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010
  • Figure 49: Prostate Cancer, Global, Licensing Agreements by Geography, 2010
  • Figure 50: Prostate Cancer, France, Provenge, Sales Forecast ($m), 2012-2020
  • Figure 51: Prostate Cancer, France, Jevtana, Sales Forecast ($m), 2011-2020
  • Figure 52: Prostate Cancer, Global, Aflibercept, Chemical Structure
  • Figure 53: Prostate Cancer, France, Aflibercept, Sales Forecast ($m), 2014-2020
  • Figure 54: Prostate Cancer, France, Ipilimumab , Sales Forecast ($m), 2014-2020
  • Figure 55: Prostate Cancer, Global, Abiraterone, Chemical Structure
  • Figure 56: Prostate Cancer, France, Abiraterone, Sales Forecast ($m), 2013-2020
  • Figure 57: Prostate Cancer, Global, Zibotentan, Chemical Structure
  • Figure 58: Prostate Cancer, France, Zibotentan , Sales Forecast ($m), 2013-2020
  • Figure 59: Prostate Cancer, France, Sprycel , Sales Forecast ($m), 2013-2020
  • Figure 60: Prostate Cancer, Global, MDV3100, Chemical Structure
  • Figure 61: Prostate Cancer, France, MDV3100 , Sales Forecast ($m), 2013-2020
  • Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010
  • Figure 63: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010
  • Figure 64: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010
  • Figure 65: Prostate Cancer, France, Prostate Cancer, Opportunity and Unmet Need, 2010
  • Figure 66: Prostate Cancer, France, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
  • Figure 67: Prostate Cancer, France, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010
  • Figure 68: Prostate Cancer, Global, Key Events Impacting the Future Market
  • Figure 69: Prostate Cancer, France, Implications for Future Market Competition, 2010
  • Figure 70: Prostate Cancer, Global, Future Players in the Market, 2010
  • Figure 71: Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010
  • Figure 72: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010
  • Figure 73: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010
  • Figure 74: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010
  • Figure 75: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010
  • Figure 76: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010
  • Figure 77: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010
  • Figure 78: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010
  • Figure 79: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010
  • Figure 80: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010
  • Figure 81: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010
  • Figure 82: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010
  • Figure 83: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010
  • Figure 84: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010
  • Figure 85: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010
  • Figure 86: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010
  • Figure 87: Prostate Cancer, Global, Medivation, SWOT Analysis 2010
  • Figure 88: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010
  • Figure 89: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010
  • Figure 90: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010
  • Figure 91: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010
  • Figure 92: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010
  • Figure 93: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010
  • Figure 94: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010
  • Figure 95: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010
  • Figure 96: Prostate Cancer, Global, M&A Deals by Deal Size, 2010
  • Figure 97: Prostate Cancer, France, Key Data Inputs from KOL Interviews, July 2010
  • Figure 98: GlobalData Market Forecasting Model
Back to Top